The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma von Beeh, Kai-Michael, MD, Kanniess, Frank, MD, Wagner, Frank, MD, Schilder, Cordula, MD, Naudts, Ingomar, MD, Hammann-Haenni, Anya, PhD, Willers, Joerg, PhD, Stocker, Hans, PhD, Mueller, Philipp, MD, Bachmann, Martin F., PhD, Renner, Wolfgang A., PhD

Volltext

Impact of guideline awareness on the counseling of patients with acute cough among general practitioners and pharmacy personnel von Kardos, Peter, Beeh, Kai-Michael, Sent, Ulrike, Bissmann, Guido

Volltext

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study von Beeh, Kai-Michael, Korn, Stephanie, Beier, Jutta, Jadayel, Dalal, Henley, Michelle, D'Andrea, Peter, Banerji, Donald

Volltext

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial von Beeh, Kai-Michael, Scheithe, Karl, Schmutzler, Heike, Krüger, Saskia

Volltext

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease von Beeh, Kai-Michael, Westerman, Jan, Kirsten, Anne-Marie, Hébert, Jacques, Grönke, Lars, Hamilton, Alan, Tetzlaff, Kay, Derom, Eric

Volltext

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis von Di Marco, Fabiano, Sotgiu, Giovanni, Santus, Pierachille, O'Donnell, Denis E, Beeh, Kai-Michael, Dore, Simone, Roggi, Maria Adelaide, Giuliani, Lisa, Blasi, Francesco, Centanni, Stefano

Volltext

Pulmonary Therapy: Looking Back on 2018 and Forward to 2019 von Beeh, Kai-Michael

Volltext

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice von Halpin, David M. G., Worsley, Sally, Ismaila, Afisi S., Beeh, Kai-Michael, Midwinter, Dawn, Kocks, Janwillem W. H., Irving, Elaine, Marin, Jose M., Martin, Neil, Tabberer, Maggie, Snowise, Neil G., Compton, Chris

Volltext

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe pers... von Beeh, Kai-Michael, LaForce, Craig, Gahlemann, Martina, Wenz, Arne, Toorawa, Robert, Fležar, Matjaž

Volltext

Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations von Kardos, Peter, Beeh, Kai-Michael, Sent, Ulrike, Mueck, Tobias, Gräter, Heidemarie, Michel, Martin C

Volltext

Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? von Micke, Patrick, Faldum, Andreas, Metz, Tsegay, Beeh, Kai-Michael, Bittinger, Fernando, Hengstler, Jan-Georg, Buhl, Roland

Volltext

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium von Beeh, Kai-Michael, Beier, Jutta, Donohue, James F

Volltext

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma von Beeh, Kai-Michael, Moroni-Zentgraf, Petra, Ablinger, Othmar, Hollaenderova, Zuzana, Unseld, Anna, Engel, Michael, Korn, Stephanie

Volltext

Improvement in quality of life with omalizumab in patients with severe allergic asthma von Chipps, Bradley, Buhl, Roland, Beeh, Kai-Michael, Fox, Howard, Thomas, Karen, Reisner, Colin

Volltext

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® s... von Beeh, K M, Derom, E, Echave-Sustaeta, J, Grönke, L, Hamilton, A, Zhai, D, Bjermer, L

Volltext

COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type‐2 and PDE4 gene expression in sputum von Singh, Dave, Bassi, Michele, Balzano, Deborah, Lucci, Germano, Emirova, Aida, Anna Nandeuil, Marie, Jellema, Gera, Afolabi, Ebenezer K., Leaker, Brian, Kornmann, Oliver, Michael Beeh, Kai, Watz, Henrik, Govoni, Mirco

Volltext

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD von Singh, Dave, Beeh, Kai Michael, Colgan, Brendan, Kornmann, Oliver, Leaker, Brian, Watz, Henrik, Lucci, Germano, Geraci, Silvia, Emirova, Aida, Govoni, Mirco, Nandeuil, Marie Anna

Volltext

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD von Govoni, Mirco, Bassi, Michele, Girardello, Luca, Lucci, Germano, Rony, François, Charretier, Rémi, Galkin, Dmitry, Faietti, Maria Laura, Pioselli, Barbara, Modafferi, Gloria, Benfeitas, Rui, Bonatti, Martina, Miglietta, Daniela, Clark, Jonathan, Pedersen, Frauke, Kirsten, Anne-Marie, Beeh, Kai-Michael, Kornmann, Oliver, Korn, Stephanie, Ludwig-Sengpiel, Andrea, Watz, Henrik

Volltext

Pulmonary Therapy 2020 Update and Podcast: Meet the Journal’s Editors-in-Chief von Beeh, Kai-Michael, Dhand, Rajiv

Volltext

Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis von Govoni, Mirco, Bassi, Michele, Vezzoli, Stefano, Lucci, Germano, Emirova, Aida, Nandeuil, Marie Anna, Petruzzelli, Stefano, Jellema, Gera L., Afolabi, Ebenezer K., Colgan, Brendan, Leaker, Brian, Kornmann, Oliver, Beeh, Kai Michael, Watz, Henrik, Singh, Dave

Volltext